All HCV treated (n = 409) | HCV treated at the NSP (n = 162) | HCV treated outside of the NSP (n = 247) | p value treated at NSP/outside of NSP | |
---|---|---|---|---|
n (%) | n (%) | n (%) | ||
Gender | n = 409 | n = 162 | n = 247 | |
Men | 318 (77.8) | 122 (75.3) | 196 (79.4) | 0.40 |
Women | 91 (22.2) | 40 (24.7) | 51 (20.6) | |
Age | n = 409 | n = 162 | n = 247 | |
Mean (SD) | 44.8 (11.1) | 46.8 (10.6) | 43.6 (11.3) | < 0.01 |
Median (range) | 45.5 (21–68) | 49.0 (22–66) | 42 (21–68) | |
Country of birth | n = 401 | n = 162 | n = 239 | |
Sweden | 346 (86.3) | 139 (85.8) | 207 (86.6) | 0.88 |
Outside of Sweden | 55 (13.7) | 23 (14.2) | 32 (13.4) | |
Living situation | n = 339 | n = 149 | n = 190 | |
House/apartment | 202 (59.6) | 81 (54.4) | 121 (63.7) | 0.09 |
Support housing | 65 (19.2) | 31 (20.8) | 34 (17.9) | 0.58 |
Treatment home | 27 (8.0) | 10 (6.7) | 17 (8.9) | 0.54 |
Prison | 5 (1.5) | 3 (2.0) | 2 (1.1) | 0.66 |
Homeless | 40 (11.8) | 24 (16.1) | 16 (8.4) | < 0.05 |
Predominantly drug injected | n = 408 | n = 162 | n = 246 | |
Stimulants/CS | 230 (56.2) | 123 (75.9) | 107 (43.4) | < 0.0001 |
Opioids/OP | 155 (37.9) | 32 (19.8) | 123 (49.8) | < 0.0001 |
Mixed CS/OP | 22 (5.5) | 7 (4.3) | 13 (6.1) | 0.82 |
Other drugs | 1 (0) | 0 | 1 (0) | – |
Duration of IDU | n = 402 | n = 160 | n = 242 | |
Mean (SD) | 22.5 (13.1) | 23.3 (13.2) | 22.0 (13.0) | 0.33 |
Median (range) | 22 (1–52) | 23.7 (1.5–51.7) | 21 (1–52) | |
OAT | n = 409 | n = 162 | n = 247 | |
Yes | 126 (30.2) | 14 (8.6) | 112 (45.3) | < 0.0001 |
No | 283 (69.1) | 148 (91.4) | 135 (54.7) | |
HIV | n = 409 | n = 162 | n = 247 | |
Positive | 27 (6.6) | 1 (0.6) | 26 (10.5) | < 0.0001 |
Negative | 382 (93.4) | 161 (99.4) | 221 (89.5) | |
HBV | n = 408 | n = 162 | n = 246 | |
HBsAg positive | 0 (0) | 0 (0) | 0 (0) | – |
Seronegative | 30 (7.3) | 12 (7.4) | 18 (7.3) | 1.00 |
Immune (post-infection) | 192 (46.9) | 76 (47.1) | 116 (47.2) | 1.00 |
Vaccinated | 186 (45.5) | 74 (45.7) | 112 (45.5) | 1.00 |